Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022804 | 0.86 | AXL (0.49) | KIF11ALDH1A1TDP1AXLTRPA1 | |
| SCHEMBL28473114 | 0.84 | KIF11 (0.33) | KIF11CA2AXL | |
| SCHEMBL28360108 | 0.84 | TRPA1 (0.42) | KIF11CA2GABRA1GABRB2CYP3A4 | |
| SCHEMBL30027744 | 0.83 | KIF11 (0.36) | KIF11CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL28994959 | 0.83 | KIF11 (0.33) | KIF11 | |
| SCHEMBL6905689 | 0.82 | AXL (0.33) | KIF11AXL | |
| SCHEMBL6067791 | 0.81 | KIF11 (0.35) | KIF11CA2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28633628 | 0.81 | KIF11 (0.35) | KIF11CA2GABRA1GABRB2CYP3A4 | |
| SCHEMBL7143644 | 0.80 | CA2 (0.47) | KIF11CA2GABRA1GABRB2ALDH1A1 | |
| SCHEMBL28320385 | 0.80 | KIF11 (0.31) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264217-B2 | Surface treatment film, manufacturing method therefor, and article | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2025-04-01 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348654-A1 | SURFACE TREATMENT FILM, MANUFACTURING METHOD THEREFOR, AND ARTICLE | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4194204-A1 | SURFACE TREATMENT FILM, MANUFACTURING METHOD THEREFOR, AND ARTICLE | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-11613618-B2 | Porous body, and method for producing porous body | EMAUS KYOTO, INC. (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20200115388-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-8123982-B2 | Dithiocarbamates provide improvement over tolyltriazole in inhibiting yellow metal corrosion | AKZO NOBEL N.V. (NL) | 2012-02-28 | — | — | US | disclosed |
| US-20050211957-A1 | Sulfur based corrosion inhibitors | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | US | disclosed |
| EP-1580301-A1 | Sulfur based corrosion inhibitors | National Starch and Chemical Investment Holding Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-0258021-B1 | METHOD OF INHIBITING THE CORROSION OF COPPER IN AQUEOUS SYSTEMS | BETZ EUROPE, INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0258021-A1 | Method of inhibiting the corrosion of copper in aqueous systems | BETZ EUROPE, INC. (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KIF11 2411/4885CA2 4029/4885GABRA1 764/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KIF11 2411/4885CA2 4029/4885GABRA1 764/4885 |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | ALK, CYP3A43, ALKBH3 | KIF11 4650/4885CA2 266/4885GABRA1 2260/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | KIF11 1229/4885CA2 3037/4885GABRA1 3287/4885 |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | KIF11 2774/4885CA2 3533/4885GABRA1 3428/4885 |
| US-20200115388-A1 | IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KIF11 2290/4885CA2 4621/4885GABRA1 1208/4885 |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | KIF11 2774/4885CA2 3533/4885GABRA1 3428/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | KIF11 2774/4885CA2 3533/4885GABRA1 3428/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KIF11 2411/4885CA2 4029/4885GABRA1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.